## PRESS RELEASE



**Wockhardt Limited** 

| Wockhardt Towers | | Bandra Kurla Complex | | Mumbai 400 051 | India | | Tel.: +91-22-2653 4444 | | www.wockhardt.com

## Wockhardt honoured with 2012 DIANA Award for Best Overall Generic Manufacturer

HDMA recognizes Wockhardt's Excellence at its 2012 Business & Leadership Conference

## Mumbai, June 17, 2012

Pharmaceutical and biotechnology major Wockhardt announced that its US subsidiary, Wockhardt USA Inc. was honoured with the presentation of the 2012 DIANA Award by the Healthcare Distribution Management Association (HDMA) for the 'Best Overall Generic Product Manufacturer' with sales of up to USD 100 million in the healthcare distributor market at their prestigious annual Business & Leadership Conference in San Antonio, Texas.

The Distribution Industry Awards for Notable Achievements in Healthcare (DIANA) Award is presented by HDMA to companies that continually foster strong trading partner relationships with the Association's primary distributor members by creating exceptional business practices that advance trade relations and benefit the entire healthcare supply chain.

"This award from HDMA is particularly significant and encouraging to Wockhardt's efforts in building strong relationships with our distributors and partners, said Wockhardt's Founder Chairman & Group CEO, Dr. Habil Khorakiwala. "We are indeed honoured and elated with this recognition from HDMA", he further added.

## **About Wockhardt:**

Wockhardt is a high-technology intensive global pharmaceutical and biotechnology company with multi-disciplinary and innovative R&D programmes. It has 3 research centres globally and manufacturing facilities across India, USA, UK and Ireland.

Wockhardt has a significant presence in USA, Europe and India, with 75% of its global revenues coming from international businesses. With a large pool of Patents and Intellectual Property knowhow, Wockhardt is home to 590 scientists, of whom 80 are doctorates. In all, Wockhardt has 158 Patents granted worldwide. In biotechnology research, it has built a competent 'Concept to Market' capabilities in all facets of development and manufacture of recombinant biopharmaceuticals.

Wockhardt boasts of a multi-ethnic workforce of more than 8000 people from 14 different nationalities.